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TENIDAP (TD) was initially defined as a dual inhibitor of
cyclooxygenase and lipoxygenase. This study was de-
signed to assess its inhibitory activity against pro-
inflammatory phosphoHpase A2. This study shows that
TD inhibits the synthesis of pro-inflammatory secretory
non-pancreatic phospholipaseA (sPLA2). Concentrations
as low as 0.251lg/ml (0.725 JIM) reduced the release of
sPLA by 40% from foetal rat calvarial osteoblasts stimu-
lated with IL-I and TNF, whereas a concentration of
2.5 tg/ml (7.25 IIM) reduced the release by over 800/0. TD
also markedly reduced the release of sPLA from
unstimulated cells. There was no direct inhibition of
sPLA enzymatic activity by TD in vitro. Northern blot
analysis showed that TD did not affect the sPLA mRNA
levels; however, immunoblotting showed a dose-depend-
ent reduction in sPLA enzyme. These results, together
with a marked reduction in sPLA enzymatic activity,
suggest that TD inhibits sPLA synthesis at the post-tran-
scriptional level. Therefore TD seems to inhibit the
arachidonic acid cascade proximally to cyclooxygenase
and ltpoxygenase and its anti-inflammatory activity may
be related at least in part to the inhibition of sPLA syn-
thesis.
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Introduction
Tenidap sodium ([Z]-5-chloro-2,3-dihydro-
3[hydroxy-2-thienylmethylene]-2-oxo-1-H-indole-1-
carboxyamide, sodium salt) (TD) is a new anti-in-
flammator agent which was originally designated
as a dual inhibitor of cyclooxygenase and
lipoxygenase.
1," It soon became apparent that TD had
other biological properties such as inhibition of IL-1
production in LPS-stimulated cells,3,4 inhibition of
the release and/or activity of collagenase and
myeloperoxidase and suppression of the expression
of circulating acute phase reactants such as serum
amyloid A in rheumatoid patients treated with TD
and of C-reactive protein in rats with adjuvant arthri-
tis. TD also inhibits bone resorption induced by
cytokines IL-1 and TNF. Since some of the above
inhibitory activities resemble those of other agents
which are known inhibitors of phospholipase a
(PEA2) we undertook a study of the impact ofTD on
the synthesis of secretory non-pancreatic PLA,.
(sPLA2) by foetal rat calvarial osteoblasts. The data
suggest that TD is a potent inhibitor of sPLA synthe-
sis. These findings add a new aspect to the spectrum
of biological activities of this compound and may
lead to a better understanding of its observed anti-
inflammatory effects.
Materials and Methods
Tenidap sodium, MW 343.75 was the kind gift of
Pfizer Canada Inc. sPLA activity was assessed as
described in detail using radiolabelled Escherichia
coli membrane phospholipid substrate. Foetal rat
calvarial cells (FRCO) were prepared as reported
previously.
I Confluent cultures of FRCO were incu-
bated in the presence of TD in concentrations rang-
ing from 0.25 l.tg/ml (0.725 l.tM) to 50 l.tg/ml (145 t.tM)
for 24 and 48 h. Foetal calf serum was withdrawn
from the medium when TD and/or IL-1 and TNF
were added to the cultures. FRCO were co-stimulated
with IL-I[ (100 U/ml or 0.2 ng/ml) and TNF0 (500 U/
ml or 25 ng/ml) as described previously.
I FRCO
viability as tested by trypan blue exclusion was
> 95%. The cells were counted at the end of each
experiment. Each experiment was performed in trip-
licate and repeated at least twice, sPLA activity was
expressed as units per ml of the medium and as units
per I x 106 cells/ml.
RNA isolation and Northern blot analysis: RNA was
isolated from cultured FRCO by the method of
Chomczynski and Sacchi. 11 Briefly, 5 x 107 to 1 x 108
cells, were homogenized using lysing buffer contain-
ing 4 M guanidium thiocyanate. RNA was purified by
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phenol:chloroform:iso-amyl alcohol extraction, fol-
lowed by two iso-propanol precipitations. RNA was
stored as an ethanol precipitate at-70C until tested.
Northern blot analysis of total RNA was performed
on 1% agarose/formaldehyde gels and the RNA was
blotted onto nitrocellulose. 12 The probe used for
hybridization was the rat sPLA cDNA. 13 The DNA
fragment was labelled by random priming
(Pharmacia) and prehybridization was done in a 50%
formamide buffer at 42C. The blot was washed in
lx55C 0.5% SDS at 50C and exposed to Kodak XAR-
film at-80C with an intensifying screen.
Western blot analysis: SDS-polyacrylamide gel
electrophoresis was done on 12% polyacrylamide
gels using the method of Laemmli. 14 Proteins were
then electrophoretically transferred to nitrocellulose
(Hybond*M-ECL, Amersham Canada, Ltd)5 for
immunoblot analysis, The primary antibody was a rat
sPLA monoclonal antibody (mAb 2E7 plus 2B9). 16
The blot was developed using enhanced
chemiluminescence (ECL) as described by the manu-
facturer (ECLTM Western blotting protocols,
Amersham International plc). The differences be-
tween sPLA2 activity in control cultures supernatants
and TD treated cells were assessed using Student’s
test.
Results
sPLA activity in culture supernatants of
unstimulated FRCO was 96 + 21 U/106 cells whereas
cells incubated in the presence of TD 5 lag/ml
(14.5 l.tM) for 48 h released 19 + 13 U/10 cells (p <
0.01). Final concentration of cells was 0.72 + 0.02 x
10/ml in controls and 0.67 + 0.03 x 10/ml in TD
treated cultures. FRCO stimulated with IL-I[ and
TNF released 8944 + 798 (SD) U/10 cells of sPLA
compared with 110 + 16 U/106 cells in unstimulated
controls. TD in concentrations of 0.25 btg/ml-0.5 btg/
ml (0.725M to 1.450 btM) reduced the release of
sPLA2 by 40%, whereas a concentration of 1.25 btg/ml
(3.625 l.tM) suppressed sPLA activity by 68%. Con-
centrations of 2.5 btg/ml (7.25 l.tM) reduced sPLA
activity by over 80% (Fig. 1). TD in concentrations
over 1.25 l.tg/ml was slightly inhibitory to cell prolif-
eration, reducing the final number of cells from 0.92
+ 0.02 x 10/ml in controls to 0.78 + 0.02 x 10/ml;
concentrations over 2.5 g/ml reduced final cell
counts to 0.63 + 0.03xl0/ml.
Northern blot analysis of FRCO total RNA showed
that TD at 1.25 t.tg/ml did not affect the level of sPLA
mRNA in unstirnulated or IL-1/TNF stimulated cells
(Fig. 2). In contrast, immunoblot analysis revealed
reduction in the quantity of sPLA in FRCO treated
with 0.25 btg/ml (0.725 btM) TD (Fig. 3). At the TD
concentration of 3.75 btg/ml (10.875 btM) the sPLA
protein became undetectable. These results suggest
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FIG. 1. Inhibition by Tenidap of the activity of phospholipase A (sPLA2) in
the supernatant of FRCO stimulated by IL-1/TNF. One lg 2.7 IM.
that TD may have a post-transcriptional effect on
sPLA2 synthesis by FRCO.
There was no direct inhibition by TD of the
enzymatic activity of recombinant human sPLA or of
the extracellular PEA of rat osteoblasts. Enzymatic
activity of recombinant human sPLA was assessed
after 60 min incubation with TD in concentrations
between 1 l.tg/ml and 50 btg/ml (2.9 btM-145 btM).
sPLA activity varied from 185 to 198 U/ml as com-
pared with the control of 195 U/ml. The activity of
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FIG. 2. Effect of Tenidap on expression of phospholipaseA (sPLA) mRNA
levels in FRCO. Northern blot hybridization using the rat sPLAcDNA probe
was run by using isolated total cellular RNA obtained from FRCO (10 lg/
lane). Lane 1, Control cells. Lane 2, IL-1/TNF treated cells. Lane 3, Tenidap
(1.25 lg/ml) treated cells. Lane 4, IL-1/TNF/Tenidap treated cells. The
lower panel shows ethidium bromide stain of 18S RNA to show equal
loading of RNA per lane of gel.Tenidap inhibits PLAe synthesis
12345
FIG. 3. Immunoblotting assay. Supernatants of FRCO cultures were used
for Western blotting and phospholipase A staining. Lane 1, Control. Lane
2, FRCO stimulated with IL-I and TNFo. Lane 3, FRCO stimulated with
IL-1 } and TNFeq coincubated with Tenidap 0.25 lg/ml (1 g/ml 2.7 pM).
Lane 4, FRCO stimulated with IL-lJ} and TNFoq coincubated with Tenidap
1.25 lg/ml. Lane 5, FRCO stimulated with IL-I} and TNFeq co-incubated
with Tenidap 3.75 g/ml. Double lower bands are caused by some protein
oxidation. Upper band in Lane 2imer of PLA2. (See References 16 and
4o).
FRCO extracellular sPLA incubated with TD (50 btg/
ml) was 63 U/ml compared with 62 U/ml in the
control.
Discussion
Early studies have identified TD as dual inhibitor
of cyclooxygenase and lipoxygenase. 1,2 TD inhibited
PGE and LTB synthesis by ionophore-stimulated
human PMNs. In rat basophilic leukaemia cells, TD
inhibited 5-HETE and LTB4 synthesis as well as
PGD2 .17 However, compared with cyclooxygenase,
the inhibition of lipoxygenase required a 14-fold
higher concentration of TD. Similar observation was
made when plasma-free leukocyte suspensions were
tested in the rat. 18 The IC50 of TD for cyclooxygenase
and lipoxygenase was 0.05 t-tM and 10 btM respec-
tively. When whole blood was used, TD did not
suppress 5-1ipoxygenase at all. It was therefore con-
cluded that, in vivo, TD is essentially a selective
inhibitor of cyclooxygenase.
18
Subsequent studies ofTD have detected its impact
on cytokine production. Endotoxin-induced IL-1
synthesis in murine peritoneal macrophages was
markedly inhibited by TD (IC50 1 btg/ml). Subcellular
studies identified the block of pro-IL-lot in the cells.
Higher concentrations of TD (10 btg/ml) also inhib-
ited IL-1 activity in LPS-stimulated human
monocytes19 and production of IL-6, and to the lesser
degree of TNF and IL-1 in LPS stimulated human
peripheral blood mononuclear cells,i TD inhibited
the release of activated collagenase and of
myeloperoxidase from neutrophils. It also inhibited
the expression of IL-1 receptor mRNA and IL-1 recep-
tor levels and reduced collagenase and stromelysin
activity in cultured normal and osteoarthritis
chondrocytes.
21 The observation that rats with
adjuvant arthritis treated with TD show marked re-
duction in the paw swelling and circulating CRP and
that human patients with rheumatoid arthritis show
reduction in circulating SAA and CRP6,2 may be
related to the above suppressive activity. Yet, in
cytokine-stimulated Hep-3B hepatoma cells in vitro,
TD was unable to block SAA synthesis. TD used
together with chemically modified tetracycline,
synergistically inhibited the tissue activity of
collagenase and gelatinase in adjuvant arthritis and
substantially reduced radiological severity of joint
damage.
22 It also inhibited cytokine-induced bone
resorption of 45Ca-labelled mouse calvaria. Some
clinical improvement was noted in a few short-term
open trials of rheumatoid arthritis and
osteoarthritis.2>25
Since TD may be potentially useful in the therapy
of inflammatory conditions, its impact on the inflam-
matory cascade is of significant interest. Secretory
non-pancreatic phospholipase a has been identified
as one of the pivotal pathogenetic agents in both
local2-28 and systemic29-31 inflammatory conditions.
Marked elevation of circulating sPLA was found in
adult and juvenile rheumatoid arthritis, correlating
well with the disease activity.32,33 sPLA also corre-
lated significantly with the complications and out-
come of septic shocM and multi-organ failure.4
sPLA2 injected into joints of experimental animals
induced dose-dependent synovitis.2<5 The synthesis
of sPLA by osteoblasts,
1 chondrocytes and smooth
muscle cells37 is induced and enhanced by cytokines,
especially IL-1 and TNF. It has recently been reported
that some agents that inhibit collagenase3 also in-
hibit sPLA2 interaction with the substrate. 39 We hy-
pothesized that TD might also inhibit sPLA synthe-
sis. Indeed, this study has shown that concentrations
as low as 0.25 I.tg/ml (0.725 btM) markedly inhibited
the synthesis of sPLA by foetal rat calvarial
osteoblasts. We have shown that the synthesis of
sPta was most probably blocked at the post-tran-
scriptional level. It has recently been reported that
TD generally inhibits protein synthesis in cells.41,42
Thus, inhibition of sPLA synthesis by TD seems to
be an important part of this general effect on cell
metabolism. TD had no direct effect on PEA
enzymatic activity.
The fact that TD inhibits the synthesis of sPLA
adds to the repertoire of its biological activities and
shows that this agent may inhibit the arachidonic
acid cascade, at a level proximal, to that of
cyclooxygenase and lipoxygenase. Marked inhibi-
tion of sPLA synthesis by TD may be partially re-
sponsible for its anti-inflammatory activity.
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